Chronic obstructive pulmonary disease: developing comprehensive management
- PMID: 14651763
Chronic obstructive pulmonary disease: developing comprehensive management
Abstract
The goals of managing chronic obstructive pulmonary disease include making the correct diagnosis, avoiding further risk (especially by smoking cessation), controlling symptoms (particularly dyspnea), and treating complications. Patients with chronic obstructive pulmonary disease can obtain substantial symptom relief from medications, including bronchodilators. Prescription of bronchodilators should be guided by the patient's degree of dyspnea, and response to initial therapy. In patients with severe disease and uncontrolled dyspnea, simultaneous use of multiple classes of bronchodilators provides additional benefit. Controlled investigations have found that patient adherence to prescribed therapies is less than optimal even in the best circumstances. Adherence barriers include factors related to the treatment, to the patient, and to the health care practitioner. Understanding these barriers and addressing patient adherence may improve outcomes. Health care practitioners need to develop an optimal working relationship with each patient and focus on their roles as educators and advocates for the patient's health. A collaborative self-management approach recognizes the patient's role in making his or her own health decisions and the physician's role as an educator and facilitator of the patient's health decisions. When multiple therapies are employed, a comprehensive management plan should be developed to help the patient understand and incorporate all the necessary treatments on an ongoing basis. Disease management programs may be useful in assisting health care practitioners and patients in managing chronic obstructive pulmonary disease.
Similar articles
-
Collaborative self-management strategies for patients with respiratory disease.Respir Care. 1994 May;39(5):566-79; discussion 579-83. Respir Care. 1994. PMID: 10146013 Review.
-
Primary care perspective on chronic obstructive pulmonary disease management.Postgrad Med. 2011 Mar;123(2):145-52. doi: 10.3810/pgm.2011.03.2272. Postgrad Med. 2011. PMID: 21474902 Review.
-
Improving in-office discussion of chronic obstructive pulmonary disease: results and recommendations from an in-office linguistic study in chronic obstructive pulmonary disease.Am J Med. 2007 Aug;120(8 Suppl 1):S28-32. doi: 10.1016/j.amjmed.2007.04.010. Am J Med. 2007. PMID: 17678941
-
The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.Am J Med. 2006 Oct;119(10 Suppl 1):63-72. doi: 10.1016/j.amjmed.2006.08.009. Am J Med. 2006. PMID: 16996901 Review.
-
The 2007 GOLD Guidelines: a comprehensive care framework.Respir Care. 2009 Aug;54(8):1040-9. Respir Care. 2009. PMID: 19650945 Review.
Cited by
-
Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease (COPD).Eur J Clin Pharmacol. 2012 Oct;68(10):1365-73. doi: 10.1007/s00228-012-1279-5. Epub 2012 Apr 5. Eur J Clin Pharmacol. 2012. PMID: 22476392
-
Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.Clin Drug Investig. 2012 Mar 1;32(3):147-55. doi: 10.2165/11630880-000000000-00000. Clin Drug Investig. 2012. PMID: 22235841 Clinical Trial.
-
Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial.Clin Drug Investig. 2019 Oct;39(10):991-1001. doi: 10.1007/s40261-019-00828-y. Clin Drug Investig. 2019. PMID: 31332649 Clinical Trial.
-
Medication adherence issues in patients treated for COPD.Int J Chron Obstruct Pulmon Dis. 2008;3(3):371-84. doi: 10.2147/copd.s3036. Int J Chron Obstruct Pulmon Dis. 2008. PMID: 18990964 Free PMC article. Review.
-
Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.Respir Res. 2014 Oct 14;15(1):123. doi: 10.1186/s12931-014-0123-0. Respir Res. 2014. PMID: 25756831 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical